Leveraging Cross-Linking Mass Spectrometry for Modeling Antibody-Antigen Complexes

J Proteome Res. 2024 Mar 1;23(3):1049-1061. doi: 10.1021/acs.jproteome.3c00816. Epub 2024 Feb 19.

Abstract

Elucidating antibody-antigen complexes at the atomic level is of utmost interest for understanding immune responses and designing better therapies. Cross-linking mass spectrometry (XL-MS) has emerged as a powerful tool for mapping protein-protein interactions, suggesting valuable structural insights. However, the use of XL-MS studies to enable epitope/paratope mapping of antibody-antigen complexes is still limited up to now. XL-MS data can be used to drive integrative modeling of antibody-antigen complexes, where cross-links information serves as distance restraints for the precise determination of binding interfaces. In this approach, XL-MS data are employed to identify connections between binding interfaces of the antibody and the antigen, thus informing molecular modeling. Current literature provides minimal input about the impact of XL-MS data on the integrative modeling of antibody-antigen complexes. Here, we applied XL-MS to retrieve information about binding interfaces of three antibody-antigen complexes. We leveraged XL-MS data to perform integrative modeling using HADDOCK (active-passive residues and distance restraints strategies) and AlphaLink2. We then compared these three approaches with initial predictions of investigated antibody-antigen complexes by AlphaFold Multimer. This work emphasizes the importance of cross-linking data in resolving conformational dynamics of antibody-antigen complexes, ultimately enhancing the design of better protein therapeutics and vaccines.

Keywords: biotherapeutics; cross-linking mass spectrometry; data-driven integrative modeling; drug discovery and development; epitope/paratope mapping.

MeSH terms

  • Antigen-Antibody Complex*
  • Epitope Mapping
  • Mass Spectrometry

Substances

  • Antigen-Antibody Complex